Skip to main content
EJNMMI Radiopharmacy and Chemistry
EJNMMI Radiopharmacy and Chemistry Cover Image

Articles

Page 4 of 5

  1. Brain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the...

    Authors: Matteo Bauckneht, Selene Capitanio, Stefano Raffa, Luca Roccatagliata, Matteo Pardini, Caterina Lapucci, Cecilia Marini, Gianmario Sambuceti, Matilde Inglese, Paolo Gallo, Diego Cecchin, Flavio Nobili and Silvia Morbelli
    Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:6
    Content type: Review Published on:

  2. L-Glutamine (L-Gln) is the most abundant amino acid present in the human body and is involved in numerous metabolic pathways. Glutaminolysis is the metabolic process deployed by many aggressive cancers such as...

    Authors: Prashanth K. Padakanti, Shihong Li, Alexander Schmitz, David Mankoff, Robert H. Mach and Hsiaoju S. Lee
    Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:5
    Content type: Research article Published on:

  3. Neuropeptide Y (NPY) has been implicated in a wide variety of physiological processes, including feeding, learning, memory, emotion, cardiovascular homeostasis, hormone secretion, and circadian rhythms. NPY Yl...

    Authors: Kazunori Kawamura, Wakana Mori, Masayuki Fujinaga, Tomoteru Yamasaki, Yiding Zhang, Hidekatsu Wakizaka, Akiko Hatori, Lin Xie, Katsushi Kumata, Takayuki Ohkubo, Yusuke Kurihara, Masanao Ogawa, Nobuki Nengaki and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:4
    Content type: Research article Published on:

  4. Clinically applied radiopharmaceuticals have to meet quality release criteria like a high radiochemical yield and radiochemical purity. Many radiopharmaceuticals do not have marketing authorization and have no...

    Authors: Erik de Blois, Rory M. S. de Zanger, Ho Sze Chan, Mark Konijnenberg and Wouter A. P. Breeman
    Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:3
    Content type: Methodology Published on:

  6. The histological evaluation of estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer lesions from biopsy tissue can stratify patients to receive endocrine therapy. Furthermore, PR e...

    Authors: Louis Allott, Cecilia Miranda, Angela Hayes, Florence Raynaud, Christopher Cawthorne and Graham Smith
    Citation: EJNMMI Radiopharmacy and Chemistry 2019 4:1
    Content type: Research article Published on:

  7. [11C]Methionine ([11C]MET) acts as an oncological radiopharmaceutical for measuring increased protein synthesis in brain tumours while having low uptake in normal brain an. In several Latin American countries, th...

    Authors: Javier Giglio, Gabriela Rosas, Martín Basso, Andrea Boné, Eduardo Savio and Henry Engler
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:15
    Content type: Methodology Published on:

  8. The free-fatty acid receptor-1 (FFA-1) is expressed by β-cells and is a promising target for molecular imaging of functional β-cell mass. Recently, the ((3-[18F]fluoropropyl)sulfonyl)propoxy-derivative of the hig...

    Authors: Mark H. Dornan, Daniil Petrenyov, José-Mathieu Simard, Antonio Aliaga, Guoming Xiong, Julien Ghislain, Barry Bedell, Vincent Poitout and Jean N. DaSilva
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:14
    Content type: Research article Published on:

  9. The metadata in the HTML format of these original articles (Eppard et al., 2017; Decristoforo & Patt, 2017; Domnanich et al., 2017; Chan et al., 2017; Jovalekic et al., 2017; Zhang & Villalobos, 2017; Meckel e...

    Authors:
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:13
    Content type: Correction Published on:

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:16

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:15

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:14

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:13

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:12

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:11

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:9

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:8

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:7

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:6

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:5

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:4

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:2

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:3

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2016 1:1

  10. We recently upgraded our [18F]fludeoxyglucose (FDG) production capabilities with the goal of futureproofing our FDG clinical supply, expanding the number of batches of FDG we can manufacture each day, and improvi...

    Authors: Alexandra R Sowa, Isaac M Jackson, Timothy J Desmond, Jeremiah Alicea, Anthony J Mufarreh, Jonathan M Pham, Jenelle Stauff, Wade P Winton, Maria V Fawaz, Bradford D Henderson, Brian G Hockley, Virginia E Rogers, Robert A Koeppe and Peter J H Scott
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:12
    Content type: Methodology Published on:

  11. Several P-glycoprotein (P-gp) substrate tracers are available to assess P-gp function in vivo, but attempts to develop a tracer for measuring expression levels of P-gp have not been successful. Recently, (Z)-2...

    Authors: Joost Verbeek, Jonas Eriksson, Stina Syvänen, Marc Huisman, Robert C. Schuit, Carla F. M. Molthoff, Rob A. Voskuyl, Elizabeth C. de Lange, Adriaan A. Lammertsma and Albert D. Windhorst
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:11
    Content type: Research article Published on:

  12. To study MMP activity in vivo in disease, several radiolabeled MMP inhibitors functioning as radiotracers have been evaluated by means of SPECT and PET. Unfortunately, most of them suffer from metabolic instab...

    Authors: Verena Hugenberg, Malte Behrends, Stefan Wagner, Sven Hermann, Michael Schäfers, Hartmuth C. Kolb, Katrin Szardenings, Joseph C. Walsh, Luis F. Gomez, Klaus Kopka and Günter Haufe
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:10
    Content type: Research article Published on:

  13. Targeted radionuclide therapy is a highly efficient but still underused treatment modality for various types of cancers that uses so far mainly readily available β-emitting radionuclides. By using α-particle e...

    Authors: Uwe Holzwarth, Isaac Ojea Jimenez and Luigi Calzolai
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:9
    Content type: Review Published on:

  14. [11C]erlotinib has been proposed as a PET tracer to visualize the mutational status of the epidermal growth factor receptor (EGFR) in cancer patients. For clinical use, a stable, reproducible and high-yielding ra...

    Authors: CĂ©cile Philippe, Severin Mairinger, Verena Pichler, Johann Stanek, Lukas Nics, Markus Mitterhauser, Marcus Hacker, Thomas Wanek, Oliver Langer and Wolfgang Wadsak
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:8
    Content type: Research article Published on:

  16. We recently developed a chelating platform based on the macrocycle 1,4,7-triazacyclononane with up to three, five-membered azaheterocyclic arms for the development of 68Ga- and 64Cu-based radiopharmaceuticals. He...

    Authors: Tilman Läppchen, Jason P. Holland, Yvonne Kiefer and Mark D. Bartholomä
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:6
    Content type: Research article Published on:

  17. 99mTc-mercaptoacetyl-triglycine (99mTc-MAG3) has been used for dynamic renal imaging since about 30 years. Free pertechnetate (99mTcO4), colloidal 99mTc ((99mTcO2)n), 99mTc-tartrate (precursor), precomplexes (99m

    Authors: Marietta Straub, Michel Leresche, Claude Pilloud, Fabien Devynck, Nicolas Stritt and Rolf Hesselmann
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:5
    Content type: Methodology Published on:

  18. Overexpression of prostatic membrane antigen (PSMA) is associated with the progression and prognosis of prostate cancer. There are numerous studies using this peptide with the 68Ga radionuclide. Previous methods ...

    Authors: Javier Giglio, Maia Zeni, Eduardo Savio and Henry Engler
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:4
    Content type: Research article Published on:

  19. The global network of cyclotrons has expanded rapidly over the last decade. The bulk of its industrial potential is composed of small medical cyclotrons with a proton energy below 20 MeV for radionuclides prod...

    Authors: Mateusz Adam Synowiecki, Lars Rutger Perk and J. Frank W. Nijsen
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:3
    Content type: Review Published on:

  20. Current analytical methods for characterizing pharmacokinetic and metabolic properties of positron emission tomography (PET) and single photon emission computed tomography (SPECT) probes are limited. Alternati...

    Authors: Eszter Boros, Omar R. Pinkhasov and Peter Caravan
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:2
    Content type: Methodology Published on:

  21. Analogues of exendin-4 have been radiolabeled for imaging the glucagon-like peptide type 1 receptors (GLP-1R) which are overexpressed in insulinoma. The aim of this research was to synthesize an 18F–labeled silic...

    Authors: Lukas O. Dialer, Andreas Jodal, Roger Schibli, Simon M. Ametamey and Martin Béhé
    Citation: EJNMMI Radiopharmacy and Chemistry 2018 3:1
    Content type: Research article Published on:

  23. Given the increasing exploration of fluorescent tracers in the field of nuclear medicine, a need has risen for practical development guidelines that can help improve the translation aspects of fluorescent trac...

    Authors: Fijs W. B. van Leeuwen, Bart Cornelissen, Federico Caobelli, Laura Evangelista, Latifa Rbah-Vidal, Silvana Del Vecchio, Catarina Xavier, Jacques Barbet and Marion de Jong
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:15
    Content type: Position Paper Published on:

  24. The favorable decay properties of 43Sc and 44Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage 43Sc (T1/2 = 3.89 h, Eβ+ av = 476 keV [8...

    Authors: Katharina A. Domnanich, Robert Eichler, Cristina MĂĽller, Sara Jordi, Vera Yakusheva, Saverio Braccini, Martin Behe, Roger Schibli, Andreas TĂĽrler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:14
    Content type: Research article Published on:

  25. Carbon-11 labeled L-methionine (11C–MET) is a popular tracer used in the clinic for imaging brain tumors with positron emission tomography. However, the stability of 11C–MET in its final formulation is not well d...

    Authors: Michael Woods, Leo Leung, Kari Frantzen, Jennifer G. Garrick, Zhengxing Zhang, Chengcheng Zhang, Wade English, Don Wilson, François Bénard and Kuo-Shyan Lin
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:13
    Content type: Methodology Published on:

  26. The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this...

    Authors: G. Bormans, A. Buck, A. Chiti, M. Cooper, J. Croasdale, M. Desruet, V. Kumar, Y. Liu, I. Penuelas, C. Rossetti, R. Schiavo, S. W. Schwarz and A. D. Windhorst
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:12
    Content type: Position paper Published on:

  28. The synthesis of [11C]L-deprenyl-D2 for imaging of astrocytosis with positron emission tomography (PET) in neurodegenerative diseases has been previously reported. [11C]L-deprenyl-D2 radiosynthesis requires a pre...

    Authors: Kevin Zirbesegger, Pablo Buccino, Ingrid Kreimerman, Henry Engler, Williams Porcal and Eduardo Savio
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:10
    Content type: Methodology Published on:

  29. The importance of the sulfur-fluorine bond is starting to increase in modern medicinal chemistry literature. This is due to a better understanding of the stability and reactivity of this moiety depending on th...

    Authors: Giancarlo Pascali, Lidia Matesic, Bo Zhang, Andrew T. King, Andrea J. Robinson, Alison T. Ung and Benjamin H. Fraser
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:9
    Content type: Review Published on:

  30. Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as an Appendix of Part B of the EANM “Guidelines on Good Radiopha...

    Authors: S. Todde, P. Kolenc Peitl, P. Elsinga, J. Koziorowski, V. Ferrari, E. M. Ocak, O. Hjelstuen, M. Patt, T. L. Mindt and M. Behe
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:8
    Content type: Guideline article Published on:

  31. [18F]AV1451 is a commonly used radiotracer for imaging tau deposits in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses of [18F]AV1451 require complex purifications to provide dose...

    Authors: Andrew V. Mossine, Allen F. Brooks, Bradford D. Henderson, Brian G. Hockley, Kirk A. Frey and Peter J. H. Scott
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:7
    Content type: Research article Published on:

  32. Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achi...

    Authors: Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré and Jacques Barbet
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:6
    Content type: Review Published on:

  33. Radiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionucli...

    Authors: Katharina A. Domnanich, Cristina Müller, Martina Benešová, Rugard Dressler, Stephanie Haller, Ulli Köster, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:5
    Content type: Research article Published on:

  34. The somatostatin receptor subtype 2 (sstr2) is expressed on a majority of luminal breast cancers, however SPECT and scintigraphy imaging with agonistic sstr2 probes has been sub-optimal. High affinity antagoni...

    Authors: Iulia Dude, Zhengxing Zhang, Julie Rousseau, Navjit Hundal-Jabal, Nadine Colpo, Helen Merkens, Kuo-Shyan Lin and François Bénard
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:4
    Content type: Research article Published on:

  35. Radiolabeled phosphatidylserine (PS)-binding peptides represent an innovative strategy for molecular imaging of apoptosis and thrombus. The hexapeptide PGDLSR was described as a selective and high affinity lig...

    Authors: Rana Ben Azzouna, Alexandre Guez, Khadija Benali, Faisal Al-Shoukr, Walter Gonzalez, Philippe Karoyan, François Rouzet and Dominique Le Guludec
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:3
    Content type: Research article Published on:

  36. The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-t...

    Authors: Andreas Poschenrieder, Margret Schottelius, Theresa Osl, Markus Schwaiger and Hans-JĂĽrgen Wester
    Citation: EJNMMI Radiopharmacy and Chemistry 2017 2:2
    Content type: Research Published on:

  38. αVβ3, αVβ5 and α5β1 integrins are known to be involved in carcinogenesis and are overexpressed in many types of tumours compared to healthy tissues; thereby they have been selected as promising therapeutic target...

    Authors: Didier J. Colin, James A. H. Inkster, Stéphane Germain and Yann Seimbille
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:16
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  39. Fast implementation of positron emission tomography (PET) into clinical and preclinical studies highly demands automated synthesis for the preparation of PET radiopharmaceuticals in a safe and reproducible man...

    Authors: Shihong Li, Alexander Schmitz, Hsiaoju Lee and Robert H. Mach
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:15
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  40. Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in ...

    Authors: M. Meckel, R. Bergmann, M. Miederer and F. Roesch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:14
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  41. Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclini...

    Authors: Lei Zhang and Anabella Villalobos
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:13
    Content type: Review Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  43. OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets

    Authors: V. Radchenko, J. W. Engle, C. Roy, J. Griswold, M. F. Nortier, E. R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M. E. Fassbender, Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo, Ait-Mohand Samia…
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1(Suppl 1):10
    Content type: Meeting abstracts Published on:

    This article is part of a Supplement: Volume 1 Supplement 1

  44. Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed t...

    Authors: Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W. Stephens
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:11
    Content type: Review Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  45. 213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide therap...

    Authors: Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong and Wouter A. P. Breeman
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:9
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  46. Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was...

    Authors: Katharina A. Domnanich, Cristina MĂĽller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas TĂĽrler and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:8
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  47. 6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) is a frequently used radiopharmaceutical for detecting neuroendocrine and brain tumors and for the differential diagnosis of Parkinson’s disease. To meet the dem...

    Authors: G. Luurtsema, H. H. Boersma, M. Schepers, A. M. T. de Vries, B. Maas, R. Zijlma, E. F. J. de Vries and P. H. Elsinga
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:7
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  48. Typically, metal-based radiopharmaceuticals are synthesized in aqueous solutions with no or low ethanol content. Labeling yields are defined by temperature, period of labeling, amount of precursor, pH etc. As ...

    Authors: Elisabeth Eppard, Marylaine Pèrez-Malo and Frank Rösch
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:6
    Content type: Research Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

  49. 149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters and stab...

    Authors: Cristina Müller, Christiaan Vermeulen, Ulli Köster, Karl Johnston, Andreas Türler, Roger Schibli and Nicholas P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2016 1:5
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2018 3:13

Submit manuscript

Follow

  • ISSN: 2365-421X (electronic)

Affiliated with

Neuer Inhalt